NCT07734766Not yet recruitingPhase 4
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
A Single-Arm Study of Ebastine as Adjuvant Therapy in Patients With Tumor Budding-Positive Hepatocellular Carcinoma After Curative Hepatectomy
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose tumors show a histopathological feature known as tumor budding, which is associated with a higher risk of postoperative recurrence. Ebastine is a second-generation antihistamine approved for allergic conditions. Preclinical studies have shown that ebastine also inhibits FAK signaling, a pathway implicated in tumor invasion, epithelial-mesenchymal transition, and recurrence. This study investigates whether administering ebastine after surgery can lower the recurrence risk associated with tumor budding-positive HCC. All enrolled participants will receive ebastine as adjuvant treatment following hepatectomy. The primary endpoint is the 1-year recurrence-free survival (RFS) rate. Secondary endpoints include 2-year RFS, overall survival, and safety. All participants in this study will receive ebastine as adjuvant (after-surgery) treatment. Researchers will monitor whether the cancer stays away for at least one year after surgery (recurrence-free survival), as well as overall survival and any side effects.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 24 Jul 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07734766
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 45
- From 1 Oct 2026 to the primary completion date, 1 Mar 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. before surgery
Other illness
- Subjects with other malignant tumors;
Age
- Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.).
Other
- Hepatocellular carcinoma that cannot be surgically resected
- Pregnant or lactating women
- Subjects who are considered unsuitable to participate in this cohort study by the investigator;
- Subjects who refuse to enroll or do not sign the informed consent form;
Who the study is looking for
- Age is ≥18 years old, male or female;
- Histologically confirmed as hepatocellular carcinoma without metastasis;
- Tumor budding is positive
- Life expectancy of at least 12 weeks;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.